Literature DB >> 16939809

Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro.

Ricardo A Dewey1, Inés Avedillo Díez, Matthias Ballmaier, Alexandra Filipovich, Johann Greil, Tayfun Güngör, Christoph Happel, Alexey Maschan, Fatih Noyan, Ulrich Pannicke, Klaus Schwarz, Scott Snapper, Karl Welte, Christoph Klein.   

Abstract

OBJECTIVE: Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency disorder characterized by recurrent infections, autoimmunity, microthrombocytopenia, and susceptibility to malignant tumors. Compared with the conventional treatment using allogeneic bone marrow transplantation, hematopoietic stem cell gene therapy might offer more specific and less toxic therapeutic options.
METHODS: We investigated retroviral WAS protein (WASP) gene transfer to assess functional correction and potential toxicities in human CD34(+) cells from WAS patients and healthy individuals, respectively.
RESULTS: WASP mRNA and protein levels were restored in CD14(+) cells derived from WASP-transduced hematopoietic stem cells. Functional reconstitution in WASP-transduced myeloid cells was documented by podosome formation and Fc gamma R-mediated phagocytosis. Importantly, overexpression of WASP in CD34(+) cells from healthy donors did not cause any discernible toxic effects.
CONCLUSIONS: Our studies document the feasibility of WASP gene transfer into human CD34(+) cells and suggest that the phenotype of WASP-deficient myeloid cells can be restored upon retroviral gene transfer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939809     DOI: 10.1016/j.exphem.2006.04.021

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function.

Authors:  Lisa S Westerberg; Miguel A de la Fuente; Fredrik Wermeling; Hans D Ochs; Mikael C I Karlsson; Scott B Snapper; Luigi D Notarangelo
Journal:  Blood       Date:  2008-09-04       Impact factor: 22.113

Review 2.  Engineering Stem Cells for Biomedical Applications.

Authors:  Perry T Yin; Edward Han; Ki-Bum Lee
Journal:  Adv Healthc Mater       Date:  2015-03-13       Impact factor: 9.933

3.  Stem-cell gene therapy for the Wiskott-Aldrich syndrome.

Authors:  Kaan Boztug; Manfred Schmidt; Adrian Schwarzer; Pinaki P Banerjee; Inés Avedillo Díez; Ricardo A Dewey; Marie Böhm; Ali Nowrouzi; Claudia R Ball; Hanno Glimm; Sonja Naundorf; Klaus Kühlcke; Rainer Blasczyk; Irina Kondratenko; László Maródi; Jordan S Orange; Christof von Kalle; Christoph Klein
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

4.  Cdc42 regulates Fc gamma receptor-mediated phagocytosis through the activation and phosphorylation of Wiskott-Aldrich syndrome protein (WASP) and neural-WASP.

Authors:  Haein Park; Dianne Cox
Journal:  Mol Biol Cell       Date:  2009-09-09       Impact factor: 4.138

5.  Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.

Authors:  Rachel M Koldej; Gael Carney; Matthew M Wielgosz; Sheng Zhou; Jun Zhan; Brian P Sorrentino; Arthur W Nienhuis
Journal:  Hum Gene Ther Clin Dev       Date:  2013-06-20       Impact factor: 5.032

Review 6.  Development of lentiviral gene therapy for Wiskott Aldrich syndrome.

Authors:  Anne Galy; Maria-Grazia Roncarolo; Adrian J Thrasher
Journal:  Expert Opin Biol Ther       Date:  2008-02       Impact factor: 4.388

7.  A numerical analysis model for interpretation of flow cytometric studies of ex vivo phagocytosis.

Authors:  Ted S Strom; Praveen Anur; Amanda Prislovsky
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

Review 8.  The identification of hematopoietic-specific regulatory elements for WASp gene expression.

Authors:  Jun Zhan; Irudayam Maria Johnson; Matthew Wielgosz; Arthur W Nienhuis
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-14       Impact factor: 6.698

Review 9.  Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges.

Authors:  Kristine E Yoder; Anthony J Rabe; Richard Fishel; Ross C Larue
Journal:  Front Mol Biosci       Date:  2021-05-12

10.  Gene therapy for Wiskott-Aldrich Syndrome-Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis.

Authors:  Christian Joerg Braun; Maximilian Witzel; Anna Paruzynski; Kaan Boztug; Christof von Kalle; Manfred Schmidt; Christoph Klein
Journal:  Rare Dis       Date:  2014-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.